Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
354 hedge funds and large institutions have $10.5B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2020 Q2 according to their latest regulatory filings, with 97 funds opening new positions, 97 increasing their positions, 133 reducing their positions, and 37 closing their positions.
162% more first-time investments, than exits
New positions opened: 97 | Existing positions closed: 37
122% more call options, than puts
Call options by funds: $48.1M | Put options by funds: $21.7M
100% more capital invested
Capital invested by funds: $5.24B → $10.5B (+$5.23B)
35% more funds holding in top 10
Funds holding in top 10: 17 → 23 (+6)
20% more funds holding
Funds holding: 295 → 354 (+59)
27% less repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 133
Top Buyers
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$168M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$63.2M |
| 3 |
D.E. Shaw & Co
New York
|
-$57.6M |
| 4 |
PC
Paulson & Co
New York
|
-$54.7M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$40.2M |
HZNP Hedge Fund Activity: Q2 2020 in Review
354 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q2 2020, worth a combined $10.5B — up 100% from $5.24B a quarter earlier.
Buyers outnumbered sellers: 97 funds opened new HZNP positions and 37 closed out — a net gain of 60 holders — while 97 added to existing stakes and 133 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $139M. The largest seller was Deerfield Management, cutting an estimated $168M.
- 354 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q2 2020, up from 295 in Q1 2020.
- Funds reported $10.5B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q2 2020, up 100% quarter-over-quarter.
- 97 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q2 2020 and 37 closed out, a net change of +60 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q2 2020 was Adage Capital Partners, an estimated $139M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q2 2020 was Deerfield Management, an estimated $168M sold.
Based on aggregated 13F filings for Q2 2020.